Opinion | Drug companies have plenty of room to negotiate

In her Sept. 14 op-ed, “The high price of Medicare’s price ‘negotiation,’” Megan McArdle reported that “a number of drugmakers have already announced they’re cutting back on development candidates in response to the new controls, and estimates from the Congressional Budget Office suggest that, thanks to the cost-control measures in the Inflation Reduction Act, we’ll end up with perhaps a dozen fewer drugs over the next couple of decades.”